Art. -Nr.: HY-19989A

MK-571 sodium

(Synonyms: L-660711 sodium)

36 Cited Publications

Kundenbewertung

Based on 36 publication(s) in Google Scholar

MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.75%
CAS. Nr.: 115103-85-0
Formel: C₂₆H₂₆ClN₂NaO₃S₂
Molecular Weight:537.07

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

MK-571 sodium Chemical Structure

CAS. Nr.: 115103-85-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (36)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

LTD₄

0.22±0.15 nM (Ki, In guinea pig lung)

LTD₄

2.1±1.8 nM (Ki, In human lung)

LTD₄

10.5 (pA2)

LTE₄

10.4 (pA2)

Alle Leukotriene Receptor Isoform-spezifische Produkte anzeigen :

Alle LPL Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	7.57 μM Compound: MK-571	Inhibition of human MRP1 in human 2008 cells Inhibition of human MRP1 in human 2008 cells	[PMID: 18707884]
MDCK-II	IC₅₀	>30 μM Compound: MK571	Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux	[PMID: 26774038]
MDCK-II	IC₅₀	20.7 μM Compound: MK-571	Inhibition of human MRP2 expressed in dog MDCK2 cells Inhibition of human MRP2 expressed in dog MDCK2 cells	[PMID: 18707884]

In Vitro

MK571 sodium (15 μM, 1 h) markedly suppresses constitutive and Ag-stimulated S1P secretion from RBL-2H3 cells and mast cells, and inhibits Fluo-3 efflux^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

RBL-2H3 cells, human LAD2 mast cells
Concentration:

15 μM
Incubation Time:

1 h
Result:

Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.

In Vivo

MK-571 sodium (0-0.5 mg/kg, orally, once) produces dose-dependent inhibition of the duration of antigen-induced dyspnea in conscious sensitized rats treated with Methysergide (3 μg/kg)^[1].
MK-571 sodium (0-1 mg/kg, orally, once) blocks LTD₄- and Ascaris-induced bronchoconstriction in conscious squirrel monkeys^[1].
MK-571 sodium (0-25 mg/kg, orally, daily, for 2 more weeks) shows reversal of hypoxic pulmonary hypertension (PH), and protects mice from hypoxic PH^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3 μg/kg methysergide, 5 min before antigen chdlenge)^[1]
Dosage:

0.5, 0.15, and 0.05 mg/kg
Administration:

Orally, once, 1 or 4 h before challenge
Result:

Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED₅₀ values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED₅₀ of 0.068 (95% CI, 0.83-0.14) mg/kg.

Animal Model:

Csnscisus squirrel msnkeys^[1]
Dosage:

0.1, 0.5, and 1 mg/kg
Administration:

Orally, once, 2 h prior to challenge with Ascaris antigen
Result:

Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in R_L and decreases in C_dyn at 1 mg/kg.

Animal Model:

FVB (Friend virus B-type) mice (Mrp4^–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O₂) in a ventilated chamber for 28 days)^[2]
Dosage:

0, 5, and 25 mg/kg
Administration:

Orally, daily, for 2 more weeks, maintain in hypoxic conditions
Result:

Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.

Chemical Information

CAS. Nr. 115103-85-0
Appearance Solid
Molecular Weight 537.07
Formel C₂₆H₂₆ClN₂NaO₃S₂
Color Light yellow to yellow
SMILES

O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O
Synonyms

L-660711 sodium
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (36)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayCell Imaging/StainingIFWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nature

Catabolism of extracellular glutathione supplies cysteine to support tumours. [Abstract]

2026 May;653(8115):933-941. PMID: 41851454
Cell

Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. [Abstract]

2023 Dec 7;186(25):5500-5516.e21. PMID: 38016470

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]

Survival curves for mice subjected to SD (SR means 48 h of recovery after SD) with oral administration of MK-571 sodium (0.1 mg/mL) (n = 10) in the drinking water compared with water controls (n = 10). The results showed that MK-571 sodium protected against SD-induced mortality.
Cancer Res

Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. [Abstract]

2026 May 27:10.1158/0008-5472.CAN-25-5172. PMID: 42200804
Nat Commun

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]

2023 Sep 19;14(1):5709. PMID: 37726279
Adv Sci (Weinh)

Fusidic Acid Reverses Chemoresistance in Breast Cancer via Targeting DDX6 to Downregulate GSK-3β/β-Catenin Signaling. [Abstract]

2025 Aug 4:e04680. PMID: 40757496
Sci Adv

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. [Abstract]

2024 Dec 13;10(50):eadq4274. PMID: 39661665

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Cells were treated with the ABCC1 inhibitor MK-571 sodium (10 μM) and MRTX849 for 3 days, followed by CCK-8 assays. The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 sodium for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
Arch Toxicol

In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. [Abstract]

2020 Nov;94(11):3799-3817. PMID: 32915249

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]

The MRP1 inhibitor MK-571 sodium (50 µM; 1 h) decreased A–B MeHg transport in MDCKII-MRP1 cells.
Cell Death Discov

Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys. [Abstract]

2024 Aug 14;10(1):364. PMID: 39143064

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]

MK-571 (5 μM, 30 min) increased the fluorescence intensity of DOX-inducible CD10⁺ PTEC CMFDA metabolites.
Food Res Int

Hydroxypropyl-β-cyclodextrin as a co-delivery vehicle for synergistically enhancing fucoxanthin oral bioavailability through dual regulation of SR-B1 and ABCB1 transporters. [Abstract]

2026 Mar 31:228:118352. PMID: 41703824
Int J Nanomedicine

The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]

2019 Nov 27:14:9217-9234. PMID: 31819426
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Sep:222:229-243. PMID: 38906233

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Sep:222:229-243. [Abstract]

HT1080 and HUH7 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).
Pharmaceutics

Study on the Effect of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Baicalin in Cells Based on MRP2, MRP3, and BCRP Efflux Transporters. [Abstract]

2024 May 29;16(6):731. PMID: 38931853
CNS Neurosci Ther

Multiple drug transporters contribute to the brain transfer of levofloxacin. [Abstract]

2023 Jan;29(1):445-457. PMID: 36253925
Commun Biol

Activation of Nrf2/HO-1 signaling pathway exacerbates cholestatic liver injury. [Abstract]

2024 May 23;7(1):621. PMID: 38783088
Int J Mol Sci

LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]

2026 Mar 13;27(6):2646. PMID: 41898509
Chem Biol Interact

A microfluidic human blood-brain barrier model reveals neurovascular toxicity and barrier disruption induced by E-cigarette additives. [Abstract]

2026 Aug 1:436:112206. PMID: 42285244
Toxicology

In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]

2025 Nov:517:154210. PMID: 40473197

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Nov:517:154210. [Abstract]

MK-571 (5 μM, 1 h) dilates the bile canalicular area in HepaRG cells.

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Nov:517:154210. [Abstract]

MK-571 (5 μM, 6 h) reduced the expression of NTCP, BSEP, and MRP3 in HepaRG cells.
J Drug Deliv Sci Technol

2025 May.
Eur J Pharm Sci

Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. [Abstract]

2023 May 1:184:106414. PMID: 36858275
Brain Res Bull

Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters. [Abstract]

2022 Oct 15:189:69-79. PMID: 35981629
Regul Toxicol Pharmacol

Characterization of in vitro Mrp2 transporter model based on intestinal organoids. [Abstract]

2019 Nov:108:104449. PMID: 31449916
Cancer Res Commun

Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]

2024 Apr 9;4(4):1024-1040. PMID: 38592451
Viruses

Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. [Abstract]

2019 Apr 24;11(4):378. PMID: 31022917
Drug Metab Dispos

Activation of pregnane X receptor-organic anion transporting polypeptide 1a/b /P-glycoprotein/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. [Abstract]

2025 Nov;53(11):100172. PMID: 41106060
J Pharm Biomed Anal

Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS. [Abstract]

2020 Sep 10:189:113441. PMID: 32615340
3 Biotech

Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]

2025 Apr;15(4):72. PMID: 40060290
J Appl Toxicol

Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters. [Abstract]

2024 Nov;44(11):1725-1741. PMID: 39030772
Toxicol Lett

SOD2 promotes the expression of ABCC2 through lncRNA CLCA3p and improves the detoxification capability of liver cells. [Abstract]

2020 Jul 1:327:9-18. PMID: 32201199
Pharmacol Res Perspect

The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by interacting with UDP-glucuronosyltransferases and efflux transport proteins. [Abstract]

2022 Feb;10(1):e00928. PMID: 35148019
Eur J Drug Metab Pharmacokinet

The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier. [Abstract]

2024 Sep;49(5):609-617. PMID: 38963639
Eur J Drug Metab Pharmacokinet

Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier. [Abstract]

2022 Mar;47(2):279-289. PMID: 35112329
Cytotechnology

Exploring the laxative effects of emodin on constipation through chloride channel activation. [Abstract]

2026 Jun;78(3):104. PMID: 42083655
Xenobiotica

The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. [Abstract]

2020 Mar;50(3):354-362. PMID: 31132291
Eberhard Karls Universität Tübingen

2022 Feb.
Biomed Pharmacother

Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. [Abstract]

2020 Sep:129:110506. PMID: 32768979

MK-571 sodium purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep:129:110506. [Abstract]

MK-571 (50 μM, 10 min) increased the accumulation of [3H]-MVC in BeWo cells.
Biomed Pharmacother

Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model. [Abstract]

2018 Oct:106:1563-1569. PMID: 30119231

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (93.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8620 mL

9.3098 mL

18.6195 mL

5 mM

0.3724 mL

1.8620 mL

3.7239 mL

10 mM

0.1862 mL

0.9310 mL

1.8620 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. [Content Brief]

[2]. Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97. [Content Brief]

[3]. Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8620 mL	9.3098 mL	18.6195 mL	46.5489 mL
	5 mM	0.3724 mL	1.8620 mL	3.7239 mL	9.3098 mL
	10 mM	0.1862 mL	0.9310 mL	1.8620 mL	4.6549 mL
	15 mM	0.1241 mL	0.6207 mL	1.2413 mL	3.1033 mL
	20 mM	0.0931 mL	0.4655 mL	0.9310 mL	2.3274 mL
	25 mM	0.0745 mL	0.3724 mL	0.7448 mL	1.8620 mL
	30 mM	0.0621 mL	0.3103 mL	0.6207 mL	1.5516 mL
	40 mM	0.0465 mL	0.2327 mL	0.4655 mL	1.1637 mL
	50 mM	0.0372 mL	0.1862 mL	0.3724 mL	0.9310 mL
	60 mM	0.0310 mL	0.1552 mL	0.3103 mL	0.7758 mL
	80 mM	0.0233 mL	0.1164 mL	0.2327 mL	0.5819 mL

MK-571 sodium

36 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MK-571 sodium

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-571 sodium

Alle Leukotriene Receptor Isoform-spezifische Produkte anzeigen

Alle LPL Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (36)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MK-571 sodium

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Anti-Cancer Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-571 sodium

Alle Leukotriene Receptor Isoform-spezifische Produkte anzeigen

Alle LPL Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (36)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MK-571 sodium Related Classifications

HY-19989A Related Classifications